Tiziana Life Sciences Ltd. (0RP)
XSTU 
Summary
0RP Chart
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded access study data suggesting the investigational therapy may deliver clinically meaningful benefits for patients. Speaking with Proactive, CEO Ivor Elrifi said the placebo-controlled study has fully enrolled 48 participants across several leading US institutions, including Harvard, Yale, Cornell, Johns Hopkins, UMass Buffalo and Thomas Jefferson.
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS), marking a key milestone for the company's lead drug candidate. The randomized, double-blind, placebo-controlled study, known as INFORM-MS (NCT06292923), is assessing the safety and potential efficacy of intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate immune activity and reduce neuroinflammation.
Tiziana Life Sciences price target boosted on foralumab update
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy” rating, following updated clinical data for its lead drug candidate, foralumab, in multiple neuroinflammatory conditions. In a note to clients, the firm wrote that it is “increasingly confident on the potential success of foralumab in multiple neuroinflammatory conditions.
Tiziana Life Sciences Ltd. (0RP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tiziana Life Sciences Ltd. ever had a stock split?
Tiziana Life Sciences Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Ivor R. Elrifi CEO | XSTU Exchange | BMG889121031 ISIN |
| GB Country | 9 Employees | - Last Dividend | 29 Oct 2019 Last Split | 24 Mar 2000 IPO Date |
Overview
Tiziana Life Sciences Ltd is a biotechnology firm based in London, the United Kingdom, established in 1998. The company is dedicated to discovering and developing innovative molecules aimed at treating human diseases, with a primary focus on oncology and immunology. Leveraging advanced biotechnological methodologies, Tiziana Life Sciences is poised to address some of the most challenging medical conditions by advancing its research in monoclonal antibodies and small molecule inhibitors.
Products and Services
Foralumab (TZLS-401): Positioned as the company's forefront candidate in immunology, Foralumab is a groundbreaking human anti-CD3 monoclonal antibody (mAb). This therapeutic agent is being explored for its potential to treat a variety of autoimmune and inflammatory diseases, including Crohn's disease, graft-versus-host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. By targeting the CD3 antigen on T-lymphocytes, Foralumab is designed to modulate immune responses, offering hope for patients suffering from these chronic conditions.
Milciclib (TZLS-201): Milciclib represents another significant facet of Tiziana's developmental portfolio. As a small molecule inhibitor, Milciclib targets a range of cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases. These kinases are pivotal in the regulation of cell growth and the malignant progression of cancer. Through the inhibition of these kinases, Milciclib has the potential to stop cancer cells from growing and dividing uncontrollably, offering a strategic approach to cancer treatment.
Anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501): This fully human monoclonal antibody is designed to block the interleukin 6 (IL6) pathway, a critical mediator of inflammation and a known contributor to autoimmune diseases and cytokine release syndrome. By targeting IL6-induced inflammation, the anti-IL6R mAb presents a promising treatment avenue for conditions driven by excessive inflammation. Additionally, its application in treating COVID-19 patients by mitigating the severe respiratory symptoms associated with the virus demonstrates the versatility and potential impact of Tiziana's research in addressing urgent global health challenges.
